Drugs
181-200 of 1,311 results
-
-
Why Covid Patients Who Could Most Benefit From Paxlovid Still Aren’t Getting It
Price worries, bureaucratic obstacles, and “I’m-over-covid-itis” slow uptake of a drug that’s complicated to take but often effective.
By Arthur Allen The State of the Union Is … Busy
Episode 337At last, Congress is getting half of its annual spending bills across the finish line, albeit five months after the start of the fiscal year. Meanwhile, President Joe Biden delivers his annual State of the Union address, an over-the-counter birth control pill is (finally) available, and controversy erupts over new public health guidelines for covid-19 isolation. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Neera Tanden, the White House domestic policy adviser, about Biden’s health agenda. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too.
-
Biden Is Right. The US Generally Pays Double That of Other Countries for Rx Drugs.
Research has consistently found that, overall, U.S. prescription drug prices are significantly higher, sometimes two to four times as high, compared with prices in other high-income industrialized countries. However, some market factors can obscure actual prices, making comparisons harder.
-
America Worries About Health Costs — And Voters Want to Hear From Biden and Republicans
The presidential election is likely to turn on the simple question of whether Americans want Donald Trump back in the White House. But health care tops the list of household financial worries for adults from both parties.
By Julie Appleby and Phil Galewitz -
Journalists Examine Medicaid Unwinding, Farmworkers’ Mental Health, and the Big Opioid Payback
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
How a Friend’s Death Turned Colorado Teens Into Anti-Overdose Activists
High school students in Colorado are pushing for a change they say is necessary to combat fentanyl poisoning: ensuring students can't get in trouble for carrying the overdose reversal drug naloxone wherever they go, including at school.
Wait, Is Insulin Cheaper Now?
Season 11, Episode 2Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
-
Patients See First Savings From Biden’s Drug Price Push, as Pharma Lines Up Its Lawyers
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
By Arthur Allen Biden Wins Early Court Test for Medicare Drug Negotiations
Episode 334A federal district court judge dismissed a lawsuit attempting to invalidate the Biden administration’s Medicare prescription-drug price negotiation program. But the suit turned on a technicality, and several more court challenges are in the pipeline. Meanwhile, health policy pops up in Super Bowl ads, as Congress approaches yet another funding deadline. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Rachel Cohrs of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
-
Journalists Catch Up on Top Issues Facing 2024 Voters, From Obamacare to Opioids
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The Struggle Over Who Gets the Last Word
Episode 332As science skepticism pervades politics, the Supreme Court will soon consider two cases that seek to define the power of “experts.” Meanwhile, abortion opponents are laying out plans for how Donald Trump, if reelected as president, could effectively curtail abortion even in states where it remains legal. Sandhya Raman of CQ Roll Call, Joanne Kenen of Johns Hopkins University and Politico Magazine, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a husband and wife who got billed for preventive care that should have been fully covered.
-
Surge in Syphilis Cases Leads Some Providers to Ration Penicillin
Injectable penicillin is the go-to treatment for syphilis and the only treatment considered safe for pregnant people with the disease. But as rates of syphilis increase across the U.S., a shortage of the injectable has prompted some public health agencies to ration it.
-
Ketamine Therapy for Mental Health a ‘Wild West’ for Doctors and Patients
Ketamine, approved by the FDA as an anesthetic in 1970, is emerging as a major alternative mental health treatment, and there are now more than 500 ketamine clinics around the country. But with little regulation and widely varying treatment protocols, it’s a medical "wild West."
By Dawn Megli -
The FTC Is Attacking Drugmakers’ ‘Patent Thickets’
It’s a big job clearing out so-called “patent thickets” drugmakers create to keep their products’ prices high. But the Federal Trade Commission is giving it a shot.
-
Records Show Publix Opioid Sales Grew Even as Addiction Crisis Prompted Other Chains’ Pullback
As national prescription drug distributors and pharmacies restricted the flow of oxycodone and other painkillers in response to the growing opioid crisis, Florida’s most popular grocery store ramped up its sales and distribution of the highly addictive drugs, according to a Tampa Bay Times analysis of federal data.
Health Enters the Presidential Race
Episode 331New Hampshire voters have spoken, and it seems increasingly clear that this November’s election will pit President Joe Biden against former President Donald Trump. Both appear to be making health a key part of their campaigns, with Trump vowing (again) to repeal the Affordable Care Act, and Biden stressing his support for contraception and abortion rights. Meanwhile, both candidates will try to highlight efforts to rein in prescription drug prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Jessie Hellmann of CQ Roll Call join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Sarah Somers of the National Health Law Program about the potential consequences for the health care system if the Supreme Court overturns a key precedent attempting to balance executive vs. judicial power.
-
-
What the Health Care Sector Was Selling at the J.P. Morgan Confab
When bankers and investors flocked to San Francisco for the largest gathering of health care industry investors, the buzz was all about artificial intelligence, the next hit weight-loss drug, and new opportunities to make money through nonprofit hospitals.
By Molly Castle Work and Arthur Allen -
Journalist Talks Distribution of Opioid Funds — And the Companies Angling for a Piece
KFF Health News senior correspondent Aneri Pattani made the rounds on national and local media in the last two weeks to discuss the opioid settlement funds flowing to state and local governments and her reporting on the topic. Here’s a collection of her appearances.